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Abstract 
Mitochondrial DNA deletions (A-mtDNAs), originally found at high levels in patients with sporadic mitochondrial encephalomy- 
opathies, have also been found to accumulate atextremely low levels during normal human aging, especially in long-lived postmitotic 
tissues uch as muscle and brain. We have now quantitated the amount of one such A-mtDNA species, the so-called 'common deletion', 
in brain regions from patients with Huntington's disease (HD). Surprisingly, we found a marked ecrease inthe amount of this A-mtDNA 
in the occipital cortex and putamen as compared to age-matched controls; however, no change was found in caudate. Using 
immunohistochemistry of brain sections, we found no differences in the staining pattern for selected respiratory chain polypeptides 
between the HD and control tissues. The reduction i  the amount of A-mtDNAs in HD may be related in part o the astrocytic gliosis in 
the affected areas, in which the deletion-rich neurons are replaced by relatively deletion-poor astrocytes. 
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1. Introduction 
Deletions of mitochondrial DNA (mtDNA) have been 
associated with progressive external ophthalmoplegia 
(PEO) and Kearns-Sayre syndrome (KSS), two related 
sporadic mitochondrial disorders [1-3], as well as with 
Pearson's marrow/pancreas syndrome, a rare hematopo- 
etic disease [4]. In these disorders, the quantity of deleted 
mtDNA (A-mtDNA) molecules is high, and can be ob- 
served easily by Southern blot hybridization analysis. Al- 
though the particular species of A-mtDNA varies among 
patients, approximately one-third of all patients harbor the 
same type of deletion, called the 'common deletion' [5,6], 
which removes 4977 bp of mtDNA between the ATPase 8 
and ND5 genes [7]. 
The 'common deletion' has also been demonstrated to 
accumulate during normal human aging, although it is 
present in extremely small amounts and is detectable only 
by the polymerase chain reaction, or PCR [8,9]. When the 
amount of this deletion was compared in different issues, 
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it was found that long-lived postmitotic tissues, such as 
muscle and brain, contained much higher amounts of 
A-mtDNA than did the other tissues tudied [ 10,11 ]. Among 
the different regions of brain, the caudate, putamen and 
substantia nigra were found to contain the highest level of 
A-mtDNA [12,13]. The variation in the amount of A- 
mtDNA between the same tissues from different persons 
of similar age appears to be less than that among tissues 
within any one individual. It has been suggested that 
certain environmental insults, such as local free radical 
production, may influence the accumulation of mtDNA 
mutations [ 14-17]. 
The analysis of mtDNA deletions has been extended to 
some age-related isorders, such as Alzheimer's disease 
(AD) and Parkinson's disease (PD), generating controver- 
sial results [18]. Ikebe et al. [8] searched for the presence 
of A-mtDNAs in brain tissue of normal subjects and of 
patients with PD, using PCR. They found that the 'com- 
mon deletion' was present in brain from all 5 PD patients 
analyzed (ages 51-77). However, the same deletion was 
also present in brain from two age-matched controls (age 
64 and 73) but not in 4 younger subjects (ages 38-57). 
Using semi-quantitative methods in a follow-up study, this 
group estimated that the 'common deletion' was present at 
a level of about 0.3% in control striatum and about 5% in 
230 x. Chen et al. / Biochimica et Biophysica Acta 1271 (1995) 229-233 
PD striatum [19]. However, the relationship between this 
level of A-mtDNA and the clinical expression of disease 
remains controversial [20-23]. 
Unlike Parkinson's disease, which is due mainly to loss 
of dopaminergic cells, Huntington's disease (HD) is asso- 
ciated with loss of other specific sets of neurons in the 
basal ganglia, including cholinergic and GABA-ergic neu- 
rons [24]. In the study reported here, we have assayed for 
the presence and amount of the 'common deletion' in 
selected brain regions from control subjects and from 
early-onset HD patients, in order to determine if the amount 
of deleted mtDNA might be increased in this devastating 
neurodegenerative disease. Surprisingly, we found just the 
opposite result. 
2. Materials and methods 
2.1. Materials 
Frozen brain tissue samples and paraffin-embedded hu-
man postmortem brain tissue were kindly provided by Dr. 
Edward Bird of the Brain Tissue Resource Center, McLean 
Hospital (Belmont, Massachussetts). The HD samples were 
deliberately chosen from 'early-onset' patients in order to 
minimize the potential confounding effects on our analyses 
of the known accumulation of mtDNA deletions with 
increasing age. The ages of the patients (all of whom were 
'grade 3' HD patients, as confirmed by postmortem patho- 
logical examination) and control subjects ranged from 
27-42 years (see Table 1). Restriction enzymes were from 
Boehringer-Mannheim and New England Biolabs; Taq 
polymerase was from Perkin-Elmer Cetus; PCR primers 
were from Genosys; [a-32 P]dATP was from DuPont-New 
England Nuclear; antibody to glial fibrillary acidic protein 
(GFAP) was from Sigma. 
2.2. Isolation of  DNA from human tissues 
DNA was extracted by the method of Davis et at. [25], 
as modified. Briefly, 50 mg of tissue were frozen in liquid 
nitrogen and crushed into powder. Five ml of RSB buffer 
(10 mM Tris. HC1, 10 mM NaC1, 25 mM EDTA, 1% 
Table 1 
Amount of 'common deletion' A-mtDNA in various brain regions from 
HD patients 
Subjects Sample # Sex Age A-mtDNA/total mtDNA (. 10 4) 
Putamen Cortex Caudate 
Control 1 b1047 42 M 6.92 0.49 6.43 
Control 2 b1366 42 M 1.41 0.15 1.54 
Control 3 b0780 27 F - 0.06 0.41 
Patient 1 b1536 36 F 0 0 1.71 
Patient 2 b1635 39 M 0.01 0.07 6.68 
Patient 3 b1264 37 F 0 0 0.90 
a A value of zero denotes a lever of detection below 0.01 - 10 -4 .  
SDS) containing 1 mg/ml  proteinase K was added and 
incubated at 50°C for at least 2 h. The solution was 
extracted with isopropanol and centrifuged. After washing 
with 70% ethanol, the DNA was precipitated with ethanol 
and then resuspended in 50 /zl H20. The concentration of
total DNA in the samples was approx. 100-500 ng//zl. 
2.3. Quantitation qj~ total mtDNA 
For quantitation of total mtDNA, total cellular DNA 
was dot-blotted onto Zeta-blot GT membranes (Bio-Rad) 
according to the manufacturer's protocol and was hy- 
bridized with mp8.M9 (an M13 clone containing mtDNA 
D-loop sequences from positions 1-740 [7]; a kind gift of 
Dr. Michael P. King) labelled by primer extension. The 
amount of total mtDNA in the samples was calculated by 
comparing the hybridizing signal to that from serial dilu- 
tions of known amounts of total HeLa cell mtDNA. 
2.4. Generation of  an mtDNA standard 
Plasmid pC was generated as an internal control for the 
direct quantitation of the 'common deletion', as described 
previously [ 10]. A fragment of deleted mtDNA was ampli- 
fied by PCR, using primers Xba8289F (mtDNA positions 
8273-8305 on the L-strand [7]) and Stu13705B (mtDNA 
positions 13720-16692 on the H-strand), and the resulting 
469-bp PCR fragment was inserted into the PCR1000 
cloning vector (Invitrogen). The insert of pC contained 
sequences from mtDNA flanking the 'common deletion', 
from positions 8273-8482 (containing tRNA Ly~ and the 
5'-end of the ATPase8 gene) and 13460-13720 (containing 
sequences from the 3'-end of the ND5 gene), with deletion 
of the intervening 4977 bp (from positions 8483-13459 
inclusive). The DNA sequence of this PCR fragment agreed 
with the published mtDNA sequence, except for a C ~ T 
transition located at nt-8382 within the ATPase8 gene. 
This change results in the creation of a new cleavage site 
at nt-8381 for the restriction endonuclease SspI 
(AATIATT; polymorphic site in bold). 
Plasmid pC DNA was purified by alkaline lysis fol- 
lowed by glassmilk absorption (Geneclean II kit, Bio 101). 
HeLa cell total mitochondrial DNA was purified by ce- 
sium chloride ultracentrifugation [26]. Both HeLa cell 
mtDNA and pC plasmid DNA were electrophoresed 
through 1% agarose gels and were quantitated by compar- 
ing the ethidium-bromide-mediated UV fluorescence with 
that generated by serially diluted DNA markers (phage A 
digested with HindIII; Boehringer-Mannheim) as a stan- 
dard. Quantitation of the standard was confirmed spec- 
trophotometrically. 
2.5. Quantitation of  the 'common deletion' 
A competitive PCR quantitation assay was used to 
quantitate the 'common deletion' in the samples [10]. 
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Fig. I. Immunohistochemical lo ization ofGFAP in brain sections of putamen. (A) Normal control. (B) Patient with HD. Note increased numbers of
astrocytes (GFAP-positive c lls) in the section from the HD patient. 
Serial dilutions of known amounts of the standard plasmid 
pC were added to the test sample and subjected to PCR 
using a single pair of primers (Xba8289F and Stu13705B). 
Digestion with SspI of the 469-bp PCR fragment derived 
from amplification of the test mtDNA should result in only 
two fragments, 293 and 176 bp long, due to cleavage at the 
single SspI site normally found in this PCR fragment, at 
nt-8449. However, the presence of the additional polymor- 
phic SspI site (at nt-8381) in the PCR fragment derived 
from amplification of the pC standard should result in 
cleavage of the 176-bp fragment into 2 smaller fragments, 
108 and 68 bp long. By separating and quantitating the 
amount of radioactivity in the test-specific (176-bp) to the 
pC standard-specific (108-bp) bands in each sample after 
polyacrylamide g l electrophoresis, we could calculate ac- 
curately the total amount of 'common deletion' present in 
the test samples [10]. 
2.6. Western blotting 
The autopsied brain tissues were homogenized with a 
Polytron homogenizer in homogenizing buffer [27]. The 
amount of total protein in each sample was measured with 
serially-diluted bovine serum albumin (Sigma) as a stan- 
dard [28]. The homogenate was mixed with an equal 
volume of 2 x SDS-PAGE loading buffer and the samples 
were boiled for 5 min before loading onto a 5-15% SDS 
gradient gel. Following electrophoresis, the separated pro- 
teins were transferred onto a nitrocellulose membrane and 
glial fibrillary acidic protein (GFAP) was revealed using 
anti-GFAP antibodies [29]. 
2.7. lmmunohistochemistry 
Immunohistochemistry was performed on 5-/xm-thick 
paraffin-embedded sections with the antibodies to subunit 
1 of Complex I (ND1) of the respiratory chain, subunit II 
of Complex IV (COX II), succinate dehydrogenase (SDH), 
and GFAP, as described [30]. 
3. Results 
3.1. Accumulation of A-mtDNAs in brain regions of HD 
patients 
The amounts of 'common deletion' A-mtDNA from 
three regions of brain (putamen, caudate, and occipital 
cortex) from three early-onset HD patients were compared 
to the same regions from age-matched control subjects. As 
shown in Table 1, the level of this A-mtDNA species in 
HD caudate was similar to that in the controls, but was 
significantly lower than in the controls (approx. by a factor 
of 1000) in the putamen and in the occipital cortex. 
3.2. Immunohistochemistry of selected mitochondrial res- 
pirato~ chain subunits in HD brain regions 
Paraffin-embedded tissues of the brain (caudate, puta- 
men, and occipital cortex) were observed by immunohisto- 
chemistry using antibodies to ND1, COII, and SDH. No 
differences in the distribution or intensities of the immuno- 
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Fig. 2. Western blot analysis of proteins from HD brain regions. Total 
protein isolated from caudate (C) and putamen (P) from control #1 and 
from the three HD patients ( ee Table 1) was subjected toSDS-PAGE 
followed by Western blot analysis with anti-GFAP antibody. Protein size 
markers, inkDa, are on the left. 
histochemical signal were found between the patients and 
controls (data not shown). 
3.3. Astrocytic gliosis in the basal ganglia of l iD brains 
Staining of the brain sections from all three regions 
with anti-GFAP antibody showed that the brains of the HD 
patients had significant astrocytic proliferation (Fig. 1). 
This was further confirmed by Western blot analysis of 
tissue homogenates of the same brain regions: there was a 
significant increase in the intensity of the signal of poly- 
peptides which migrated in the gel at a position corre- 
sponding to GFAP (40-50 kDa), and which displayed 
immunoreactivity to anti-GFAP antibody (Fig. 2). 
4. Discussion 
Huntington's disease is an autosomal dominant disorder 
characterized by the clinical manifestations of chorea, 
decreased muscular tone, and dementia. While the chorea 
is thought o be caused by nerve cell death (up to 90%) in 
the striatum, the impaired cognitive functions and eventual 
dementia may be due either to the concomitant loss of 
cortical neurons or to the disruption of normal activity in 
the cognitive portions of the basal ganglia [31 ]. 
We have quantitated the amount of 'common deletion' 
in selected affected brain regions from early-onset HD 
patients. Unlike what has been reported in Parkinson's 
disease (i.e., significant increase [8,19] or no difference 
[22,23]), we have found that the putamen and cortex of 
patients with Huntington's disease contained significantly 
less of this species of mtDNA deletion as compared to the 
controls. However, we observed no quantitative differ- 
ences in the caudate. 
These results could be due to the involvement of com- 
pletely different subsets of neurons in the pathogenesis of
HD as compared to PD (substantia nigra was not analyzed 
in this study). The differences we observed in the amount 
of A-mtDNA between the putamen and caudate is unclear, 
but could be due to structural and functional heterogeneity 
in the basal ganglia; it has been demonstrated that there are 
subsets of neurons in this region that differ from each 
other based on their content of particular substances, uch 
as acetylcholinesterase (ACHE) and diaphorase. Further- 
more, the neurons in this area appear to receive distinct 
cortical inputs and also to project differently. In Huntin- 
gon's disease, these neurons might also be affected iffer- 
ently in the disease process [32]. The most consistent 
postmortem findings are basal ganglia atrophy with neu- 
ronal loss and gliosis in the striatum and globus pallidus. 
The loss of medium spiny GABA-ergic neurons, with 
marked reductions in glutamate decarboxylase and GABA, 
and loss of GABA-ergic projections from the striatum, are 
the most characteristic and severe abnormalities in HD. 
This pattern of neuronal loss correlates with the significant 
reduction in the amount of 'common deletion' A-mtDA 
present in the putamen and cortex of HD brain. Interest- 
ingly, we have obtained similar results in some patients 
with Alzheimer's disease (our unpublished ata). 
Immunohistochemical examination of basal ganglia and 
cortex with anti-GFAP demonstrated a significant increase 
of astrocytes in the affected areas. We suspect hat the 
reduction in the level of deleted mtDNA in HD may be 
due, at least in part, to the combined effect of neuronal 
loss and astrocytic gliosis. The limited data on the accumu- 
lation of mtDNA deletions indicate that long-lived tissues, 
such as heart and skeletal muscle, accumulate A-mtDNAs 
to a much greater extent than do tissues that turn over 
rapidly, such as liver [10]. One would predict hat neurons, 
which are long-lived, would therefore accumulate A- 
mtDNAs to a much greater extent han would glia, which 
turn over relatively rapidly. Since it is known that neurons 
are lost in HD and are replaced by glia, the net amount of 
A-mtDNAs would decrease in HD, owing to the combined 
effects of loss of A-mtDNA-rich neurons and gain of 
A-mtDNA-poor astrocytes. 
Because of the extensive atrophy observed in the stria- 
tum of our samples, there may have been serious variations 
in the sampling of this region. In order to minimize this 
problem and to correlate the degree of astrocytosis with 
changes in A-mtDNA levels, we performed the Western 
blot analysis to detect GFAP on the same tissue samples 
that were used to perform the quantitation of A-mtDNA. 
Both the putamen and caudate from HD patients contained 
more GFAP, as measured by Western blotting, as com- 
pared to the same regions from normal controls, confirm- 
ing previous studies [33,34]. For this reason, we believe 
that our failure to detect the 1000-fold reduction in A- 
mtDNA in HD caudate that was observed in putamen and 
occipital cortex is real. If true, this finding demonstrates 
that alterations in the levels of A-mtDNAs in HD brain 
cannot be due merely to replacement of neurons by astro- 
cytes. This conclusion is supported by the fact that a rough 
calculation of the amount of A-mtDNA present in long- 
lived neurons vs. rapidly-turning-over astrocytes alone 
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cannot explain a 1000-fold difference in A-mtDNA levels 
between these two cell types. Other factors, which are 
unknown at present, most likely are involved. For exam- 
ple, the level of deletion might be specific to neuronal 
subtypes, such that some cells (e.g., dopaminergic neu- 
rons) might harbor one level of A-mtDNA, while others 
(e.g., cholinergic and GABA-ergic neurons) might harbor 
significantly different levels. This supposition is consistent 
with the finding that A-mtDNA levels vary significantly 
among brain subregions in normal aged individuals, with 
striatum containing approx. 200-fold more A-mtDNAs 
than cerebellum [12,13]. Interestingly, this difference was 
observed even in the pathogenic situation, as cerebellum 
from a patient with sporadic Kearns-Sayre syndrome har- 
boring the 'common deletion' had one-third as much A- 
mtDNAs as did frontal cortex [35]. 
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